Insight Molecular Diagnostics Inc. IMDX
Revenue compounded at +27.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Operating income $B | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | · | −0.0 | −0.0 | · | · | · | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.65 | −4.66 | −3.75 | −13.25 | −0.72 | −0.46 | −0.44 | −0.42 | −0.64 | −0.42 | −0.42 | −0.27 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | −1480.7 | −101.5 | −146.5 | −129.9 | −93.1 | −130.9 | −402.6 | −271.6 | −110.1 | −187.0 | · |
| Shares out B | 0.03 | 0.02 | 0.01 | 0.01 | 0.09 | 0.07 | 0.06 | 0.04 | 0.03 | 0.03 | 0.03 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 8 of 19 fiscal years. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 43 checks could not be computed.